IPHA
Innate Pharma S.A. ADS
Biological Products, (No Diagnostic Substances)
Best Biotech Stocks 2026 →
Innate Pharma S.A. ADS (IPHA) Stock: Buy, Sell, or Hold?
$1.49
-0.10 (-6.29%)
âŧ
5d:
+6.43%
30d:
+4.2%
90d:
-31.65%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (70%)
Quality Score
44/100
Position
FAIR
30-Day Fair Range
$1.43 â $1.56
Position: FAIR
Forward P/E & Valuation
-3.2x
Next 12M consensus est.
Wall Street Target
$7.00
+369.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.32 / $1.61
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: IPHA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When IPHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: IPHA is currently trading at $1.49, which is considered fair relative to its 30-day fair value range of $1.43 to $1.56.
Technical Outlook: Technically, IPHA is in a downtrend. Immediate support is located at $1.32, while resistance sits at $1.61. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.00 (+369.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IPHA is in a downtrend. Immediate support is located at $1.32, while resistance sits at $1.61. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.00 (+369.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.43 -
$1.56
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
Trading Range & Key Levels
30-Day Trading Range
$1.43 -
$1.56
Current vs Trading Range
FAIR
Support Level
$1.32
Resistance Level
$1.61
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 369.8% below Wall St target ($7.00)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-3.20
Wall Street Target
$7.00
(+369.8%)
Revenue Growth (YoY)
16.5%
Earnings Growth (YoY)
-74.7%
Share IPHA Analysis
Share this live IPHA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 12, 2026 7:18 PM ET
Data refreshes hourly during market hours. Next update: 8:18 PM
Data refreshes hourly during market hours. Next update: 8:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 41 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 42 HOLD |
|
SNDX
Syndax Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$35 | 58 HOLD |
|
ACHV
Achieve Life Sciences Inc |
STRONG BUY
12 analysts |
$14 | 56 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
18 analysts |
$72 | 25 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive IPHA Research Pages
